Literature DB >> 20822347

MMR vaccination and disease elimination: the Finnish experience.

Irja Davidkin1, Mia Kontio, Mikko Paunio, Heikki Peltola.   

Abstract

Measles, mumps and rubella (MMR) vaccinations have been included in Finland's national vaccination program as a two-dose schedule since 1982. Owing to the high (>95%) coverage of vaccinations, indigenous MMR diseases were eliminated from Finland by the mid-1990s. In 1982, the incidence of measles, mumps and rubella was 105, 43 and 64 per 100,000 population, respectively, but declined to 0.1 per 100,000 population for all MMR diseases in 1995. Since then, the few cases of measles, mumps and rubella imported annually have not caused any outbreaks. Several research projects that started along with the vaccination campaign have provided important support throughout the program. The vaccine was proven to be safe, immunogenic and effective. Antibody follow-up has revealed that MMR vaccine-induced antibodies wane over time, and concerns have arisen about the continuation of this good situation. High vaccination coverage, enhanced surveillance and preparedness to administer additional doses when needed are key factors for future success. Here we present an overview of MMR vaccinations and the Finnish experience of the MMR disease elimination process, and we describe surveillance activities in the era following elimination in Finland.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20822347     DOI: 10.1586/erv.10.99

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  13 in total

1.  Outbreak of mumps in a student population with high vaccination coverage in China: time for two-dose vaccination.

Authors:  Wei Qin; Yao Wang; Tao Yang; Xiao-Kang Xu; Xiang-Mei Meng; Chang-Jun Zhao; Shao-Yi Li; Shao-Yu Xie; Kai-Chun Li; Hong Su
Journal:  Hum Vaccin Immunother       Date:  2019-03-15       Impact factor: 3.452

2.  Mumps Virus SH Protein Inhibits NF-κB Activation by Interacting with Tumor Necrosis Factor Receptor 1, Interleukin-1 Receptor 1, and Toll-Like Receptor 3 Complexes.

Authors:  Stephanie Franz; Paul Rennert; Maria Woznik; Josephine Grützke; Amy Lüdde; Eva Maria Arriero Pais; Tim Finsterbusch; Henriette Geyer; Annette Mankertz; Nicole Friedrich
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

3.  Susceptibility to measles, mumps, and rubella in 5-year-old children in Flanders, Belgium.

Authors:  E Leuridan; K Maertens; M Wautier; V Hutse; H Theeten
Journal:  Eur J Pediatr       Date:  2015-01-13       Impact factor: 3.183

Review 4.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2021-11-22

5.  Outbreak-related mumps vaccine effectiveness among a cohort of children and of young adults in Germany 2011.

Authors:  Anja Takla; Merle M Böhmer; Christina Klinc; Norbert Kurz; Alice Schaffer; Heribert Stich; Petra Stöcker; Ole Wichmann; Judith Koch
Journal:  Hum Vaccin Immunother       Date:  2013-10-07       Impact factor: 3.452

6.  Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage.

Authors:  Sandra Waaijenborg; Susan J M Hahné; Liesbeth Mollema; Gaby P Smits; Guy A M Berbers; Fiona R M van der Klis; Hester E de Melker; Jacco Wallinga
Journal:  J Infect Dis       Date:  2013-05-08       Impact factor: 5.226

7.  Seroepidemiology of mumps in Europe (1996-2008): why do outbreaks occur in highly vaccinated populations?

Authors:  J Eriksen; I Davidkin; G Kafatos; N Andrews; C Barbara; D Cohen; A Duks; A Griskevicius; K Johansen; K Bartha; B Kriz; G Mitis; J Mossong; A Nardone; D O'Flanagan; F DE Ory; A Pistol; H Theeten; K Prosenc; M Slacikova; R Pebody
Journal:  Epidemiol Infect       Date:  2012-06-12       Impact factor: 4.434

8.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2020-04-20

9.  Cost of Public Health Response and Outbreak Control With a Third Dose of Measles-Mumps-Rubella Vaccine During a University Mumps Outbreak-Iowa, 2015-2016.

Authors:  Mona Marin; Tricia L Kitzmann; Lisa James; Patricia Quinlisk; Wade K Aldous; John Zhang; Cristina V Cardemil; Chris Galeazzi; Manisha Patel; Ismael R Ortega-Sanchez
Journal:  Open Forum Infect Dis       Date:  2018-10-04       Impact factor: 3.835

10.  Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.

Authors:  Sanjay Lalwani; Sukanta Chatterjee; Sundaram Balasubramanian; Ashish Bavdekar; Shailesh Mehta; Sanjoy Datta; Michael Povey; Ouzama Henry
Journal:  BMJ Open       Date:  2015-09-11       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.